基于组学技术的中医药防治肝纤维化基础研究进展

吴建芝; 黄彬; 郭津丞; 杨志云; 李晓骄阳

doi:10.12449/JCH251005

基于组学技术的中医药防治肝纤维化基础研究进展

DOI: 10.12449/JCH251005

吴建芝^{1, 2},
黄彬⁴,
郭津丞³,
杨志云⁵,
李晓骄阳^2, , ,

1.
天府锦城实验室（前沿医学中心），成都 610212
2.
北京中医药大学生命科学学院，北京 100029
3.
北京中医药大学中医学院，北京 100029
4.
福建中医药大学中西医结合研究院，福州 350122
5.
首都医科大学附属北京地坛医院中西医结合二科，北京 100015

基金项目:

国家中医药现代化重点研发计划项目 (2022YFC3502100)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：李晓骄阳负责拟定写作思路；吴建芝、黄彬负责资料分析，撰写论文；郭津丞、杨志云负责修改论文；李晓骄阳负责指导撰写文章并最后定稿。

详细信息

通信作者:
李晓骄阳， xiaojiaoyang.li@bucm.edu.cn （ORCID： 0000-0003-0291-5856）

计量
- 文章访问数: 73
- HTML全文浏览量: 27
- PDF下载量: 22
- 被引次数: 0
出版历程
- 收稿日期: 2025-06-27
- 录用日期: 2025-08-02
- 出版日期: 2025-10-25

Advances in the basic research on traditional Chinese medicine for prevention and treatment of hepatic fibrosis based on omics technology

1.
Frontiers Medical Center，Tianfu Jincheng Laboratory，Chengdu 610212，China
2.
School of Life Sciences Beijing University of Chinese Medicine Beijing 100029，China
3.
School of Traditional Chinese Medicine，Beijing University of Chinese Medicine，Beijing 100029，China
4.
Institute of Integrated Chinese and Western Medicine，Fujian University of Traditional Chinese Medicine，Fuzhou 350122，China
5.
Second Department of Integrated Traditional Chinese and Western Medicine，Beijing Ditan Hospital，Capital Medical University，Beijing 100015，China

Research funding:

National Key R&D Program Research on Modernization of Traditional Chinese Medicine (2022YFC3502100)

More Information

Corresponding author: LI Xiaojiaoyang， xiaojiaoyang.li@bucm.edu.cn （ORCID： 0000-0003-0291-5856）

摘要

摘要: 肝纤维化是多种慢性肝病的关键共性病理环节，可进展为肝硬化、肝癌等重大恶性疾病，然而目前仍缺乏高效、靶向的治疗药物。传统中医药防治肝纤维化的临床疗效明确，但复方成分的复杂性及作用机制欠明，严重阻碍其临床精准应用和国际化推广。近年来，多模态高通量组学技术快速发展，凭借其系统性分析、大数据运算和靶点精准预测的集群优势，为阐释中医药治疗重大疑难疾病的科学内涵提供了强大技术支撑。尤其是转录组学、蛋白质组学及代谢组学等多维整合策略，可全景式解析中药复方及单体成分改善肝纤维化的关键信号通路群、细胞表型转化模式和细胞外基质代谢稳态的深层分子网络，并助力中药有效成分群及新型生物标志物的筛选与评价。本文梳理了近5年应用多组学技术探讨中医药防治肝纤维化的基础研究进展，通过汇总“药物-靶点-通路-表型”关联网络以深度解析中药调控肝星状细胞活化等表型改变及逆转肝纤维化的核心机制。未来研究需进一步深入挖掘多组学技术的交叉融合与动态分析方法，助力精准辨识中药调控核心靶标网络，并系统解析复方配伍规律的科学内涵，以期为开发高效靶向抗肝纤维化药物及个体化诊疗策略提供理论依据。
- 肝纤维化 /
- 抗肝纤维化药（中药） /
- 转录组学 /
- 蛋白质组学 /
- 代谢组学
Abstract: Hepatic fibrosis is the common key pathological link of various chronic liver diseases and can progress to malignant diseases such as liver cirrhosis and hepatocellular carcinoma； however， there is still a lack of effective targeted therapeutic drugs at present. Traditional Chinese medicine （TCM） has a marked clinical effect in the prevention and treatment of hepatic fibrosis， yet its precise clinical application and global promotion are greatly limited by the complex components of compound prescriptions and unclear mechanism of action. In recent years， multimodal high-throughput omics technology has achieved rapid development， providing strong technical support for elaborating on the scientific connotation of TCM in the treatment of complex diseases due to its advantages of systematic profiling， big-data analytics， and precise target prediction. In particular， integrated transcriptomic， proteomic， and metabolomic strategies comprehensively elucidate key signaling networks， cellular phenotypic transitions， and extracellular matrix metabolic homeostasis modulated by TCM compounds and monomers and assist in the screening and assessment of effective component groups and novel biomarkers. This article systematically reviews the advances in basic research on TCM prevention and treatment of hepatic fibrosis based on multi-omics technologies in the past five years， summarizes the “drug-target-pathway-phenotype” regulatory network， and elaborates on the core mechanisms of TCM in regulating hepatic stellate cell activation and reversing hepatic fibrosis. Future studies should further delve into the interdisciplinary integration and dynamic analytical methodologies of multi-omics technologies， precisely identify the core regulatory target networks modulated by TCM， and systematically unravel the scientific connotation of compatibility rule in compound prescriptions， in order to provide a theoretical basis for developing efficient targeted drugs for hepatic fibrosis and individualized diagnosis and treatment strategies.
- Hepatic Fibrosis /
- Anti-Hepato Fibrosis Agents （TCD） /
- Transcriptomics /
- Proteomics /
- Metabolomics

HTML全文

参考文献(36)

[1]	GUO C, LAI LY, MA BY, et al. Notoginsenoside R1 targets PPAR-γ to inhibit hepatic stellate cell activation and ameliorates liver fibrosis[J]. Exp Cell Res, 2024, 437( 1): 113992. DOI: 10.1016/j.yexcr.2024.113992.
[2]	BAI YM, LIANG S, ZHOU YH, et al. Transcriptomic analysis reveals pharmacological mechanisms mediating efficacy of Yangyinghuoxue Decoction in CCl₄-induced hepatic fibrosis in rats[J]. Front Pharmacol, 2024, 15: 1364023. DOI: 10.3389/fphar.2024.1364023.
[3]	ZHANG JJ, ZHANG JX, FENG QY, et al. Eriocitrin ameliorates hepatic fibrosis and inflammation: The involvement of PPARα-mediated NLRP1/NLRC4 inflammasome signaling cascades[J]. J Ethnopharmacol, 2025, 338( Pt 3): 119119. DOI: 10.1016/j.jep.2024.119119.
[4]	YANG Y, SUN MY, LI WD, et al. Rebalancing TGF-β/Smad7 signaling via Compound Kushen injection in hepatic stellate cells protects against liver fibrosis and hepatocarcinogenesis[J]. Clin Transl Med, 2021, 11( 7): e410. DOI: 10.1002/ctm2.410.
[5]	ZHOU QM, ZHANG X, CHEN S, et al. Shugan Jianpi Formula attenuate liver fibrosis via regulation of miR-193a-3p/TGF-β2 in hepatic stellate cells: An in vivo and in vitro study[J]. J Ethnopharmacol, 2025, 340: 119120. DOI: 10.1016/j.jep.2024.119120.
[6]	CHEN XF, WANG YM, JI SX, et al. Hepatoprotective efficacy and interventional mechanism of Qijia Rougan decoction in liver fibrosis[J]. Front Pharmacol, 2022, 13: 911250. DOI: 10.3389/fphar.2022.911250.
[7]	XIONG Y, HU JY, XUAN C, et al. Transcriptome analysis reveals the molecular mechanism of Yiqi Rougan decoction in reducing CCl₄-induced liver fibrosis in rats[J]. Chin Med, 2021, 16( 1): 142. DOI: 10.1186/s13020-021-00552-w.
[8]	WANG T, ZHU JH, GAO LH, et al. Identification of circular RNA biomarkers for Pien Tze Huang treatment of CCl₄-induced liver fibrosis using RNA-sequencing[J]. Mol Med Rep, 2022, 26( 4): 309. DOI: 10.3892/mmr.2022.12825.
[9]	DENG J, LONG J, YANG Y, et al. Gentiana decoction inhibits liver fibrosis and the activation of hepatic stellate cells via upregulating the expression of Parkin[J]. Fitoterapia, 2024, 178: 106170. DOI: 10.1016/j.fitote.2024.106170.
[10]	MA Z, XUE XY, BAI JZ, et al. Si-Wu-Tang ameliorates bile duct ligation-induced liver fibrosis via modulating immune environment[J]. Biomed Pharmacother, 2022, 155: 113834. DOI: 10.1016/j.biopha.2022.113834.
[11]	LAN T, CHEN B, HU XZ, et al. Tianhuang formula ameliorates liver fibrosis by inhibiting CCL2-CCR2 axis and MAPK/NF-κB signaling pathway[J]. J Ethnopharmacol, 2024, 321: 117516. DOI: 10.1016/j.jep.2023.117516.
[12]	MENG Q, ZHU HW, LI YY, et al. Quantitative proteomics reveals the protective effects of Yinchenzhufu decoction against cholestatic liver fibrosis in mice by inhibiting the PDGFRβ/PI3K/AKT pathway[J]. Front Pharmacol, 2024, 15: 1341020. DOI: 10.3389/fphar.2024.1341020.
[13]	GONG PY, YIN KH, LUO XM, et al. Tandem mass tag-based proteomics analysis reveals the multitarget mechanisms of Phyllanthus emblica against liver fibrosis[J]. Front Pharmacol, 2022, 13: 989995. DOI: 10.3389/fphar.2022.989995.
[14]	CHEN XF, SUN X, JI SX, et al. TMT-based proteomics analysis identifies the interventional mechanisms of Qijia Rougan decoction in improving hepatic fibrosis[J]. J Ethnopharmacol, 2024, 319( Pt 3): 117334. DOI: 10.1016/j.jep.2023.117334.
[15]	ZHANG JB, JIN HL, FENG XY, et al. The combination of Lonicerae Japonicae Flos and Forsythiae Fructus herb-pair alleviated inflammation in liver fibrosis[J]. Front Pharmacol, 2022, 13: 984611. DOI: 10.3389/fphar.2022.984611.
[16]	ZHANG YM, ZHAO M, LIU YY, et al. Investigation of the therapeutic effect of Yinchen Wuling Powder on CCl₄-induced hepatic fibrosis in rats by ¹H NMR and MS-based metabolomics analysis[J]. J Pharm Biomed Anal, 2021, 200: 114073. DOI: 10.1016/j.jpba.2021.114073.
[17]	WANG C, MA C, FU K, et al. Hepatoprotective effect of phillygenin on carbon tetrachloride-induced liver fibrosis and its effects on short chain fatty acid and bile acid metabolism[J]. J Ethnopharmacol, 2022, 296: 115478. DOI: 10.1016/j.jep.2022.115478.
[18]	YANG YX, CHEN YC, FENG DG, et al. Ficus hirta Vahl. ameliorates liver fibrosis by triggering hepatic stellate cell ferroptosis through GSH/GPX4 pathway[J]. J Ethnopharmacol, 2024, 334: 118557. DOI: 10.1016/j.jep.2024.118557.
[19]	HAO M, CHEN ZY, WANG PP, et al. Bioactive fraction of processed Curcumae Rhizoma-Sparganii Rhizoma anti-liver fibrosis by regulate taurine metabolism through PI3K/AKT pathway[J]. J Ethnopharmacol, 2025, 351: 120090. DOI: 10.1016/j.jep.2025.120090.
[20]	CHEN Y, LIAO W, ZHU ZP, et al. Essential oil from the raw and vinegar-processed Rhizoma Curcumae ameliorate CCl₄-induced liver fibrosis: Integrating network pharmacology and molecular mechanism evaluation[J]. Food Funct, 2021, 12( 9): 4199- 4220. DOI: 10.1039/d0fo03052j.
[21]	ZHOU Y, WU R, CAI FF, et al. Xiaoyaosan decoction alleviated rat liver fibrosis via the TGFβ/Smad and Akt/FoxO3 signaling pathways based on network pharmacology analysis[J]. J Ethnopharmacol, 2021, 264: 113021. DOI: 10.1016/j.jep.2020.113021.
[22]	YAN D, ZHANG XL, MA CM, et al. Mechanism study of Xiaoyao San against nonalcoholic steatohepatitis-related liver fibrosis based on a combined strategy of transcriptome analysis and network pharmacology[J]. Pharmaceuticals(Basel), 2024, 17( 9): 1128. DOI: 10.3390/ph17091128.
[23]	HONG B, WANG YP, HOU YJ, et al. Study on the mechanism of anti-hepatic fibrosis of Glycyrrhiza Uralensis-Salvia miltiorrhiza prescription based on serum and urine metabolomics and network pharmacology[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2022, 1209: 123416. DOI: 10.1016/j.jchromb.2022.123416.
[24]	LI Y, LI MX, MAO J, et al. The processing mechanism of vinegar-processed Curcumae Rhizome enhances anti hepatic fibrotic effects through regulation of PI3K/Akt/mTOR signaling pathway[J]. Phytomedicine, 2024, 135: 156098. DOI: 10.1016/j.phymed.2024.156098.
[25]	CAO KF, JIANG H, ZHANG LL, et al. Effective components and molecular mechanism of Biejiaruangan capsule against liver fibrosis: High-resolution mass spectrometry, network pharmacological analysis and experimental verification[J]. Comb Chem High Throughput Screen, 2024. DOI: 10.2174/0113862073338867240930031800.[ Epub ahead of print]
[26]	CHEN ST, ZHU YP, WANG JX, et al. Biejia Ruangan tablet alleviated liver fibrosis in murine models by hindering the crosstalk between hepatic stellate cells and M2-like macrophages through PDGF-AA/PI3K/AKT pathway[J]. J Ethnopharmacol, 2025, 350: 120029. DOI: 10.1016/j.jep.2025.120029.
[27]	WU JZ, GONG LP, LI YF, et al. Tao-Hong-Si-Wu-Tang improves thioacetamide-induced liver fibrosis by reversing ACSL4-mediated lipid accumulation and promoting mitophagy[J]. J Ethnopharmacol, 2024, 333: 118456. DOI: 10.1016/j.jep.2024.118456.
[28]	ZHU JH, ZHANG D, WANG T, et al. Target identification of hepatic fibrosis using Pien Tze Huang based on mRNA and lncRNA[J]. Sci Rep, 2021, 11( 1): 16980. DOI: 10.1038/s41598-021-96459-5.
[29]	LIU ZY, XIANG HY, XIANG DJ, et al. Revealing potential anti-fibrotic mechanism of Ganxianfang formula based on RNA sequence[J]. Chin Med, 2022, 17( 1): 23. DOI: 10.1186/s13020-022-00579-7.
[30]	YANG YH, LIU Y, CHENG YJ, et al. Multi-omics and experimental analysis unveil the key components in Scutellaria baicalensis Georgi to alleviate hepatic fibrosis via regulating cPLA2-mediated arachidonic acid metabolism[J]. J Transl Med, 2024, 22( 1): 1138. DOI: 10.1186/s12967-024-05955-5.
[31]	GAO Y, WU H, LUO YQ, et al. Mechanisms of dihydromyricetin for improving hepatic fibrosis through the integration of metabolomics and gut microbiota[J]. Am J Chin Med, 2025, 53( 3): 889- 908. DOI: 10.1142/S0192415X25500338.
[32]	ZHANG YM, ZHAO M, JIANG X, et al. Comprehensive analysis of fecal microbiome and metabolomics in hepatic fibrosis rats reveal hepatoprotective effects of Yinchen Wuling Powder from the host-microbial metabolic axis[J]. Front Pharmacol, 2021, 12: 713197. DOI: 10.3389/fphar.2021.713197.
[33]	LI X, XU XY, TAO SA, et al. Gut microbes combined with metabolomics reveal the protective effects of Qijia Rougan decoction against CCl₄-induced hepatic fibrosis[J]. Front Pharmacol, 2024, 15: 1347120. DOI: 10.3389/fphar.2024.1347120.
[34]	CUI XY, ZHANG RH, LI YF, et al. Bie Jia Jian pill ameliorates BDL-induced cholestatic hepatic fibrosis in rats by regulating intestinal microbial composition and TMAO-mediated PI3K/AKT signaling pathway[J]. J Ethnopharmacol, 2025, 337( Pt 2): 118910. DOI: 10.1016/j.jep.2024.118910.
[35]	ZHAO YH, ZHAO M, ZHANG YM, et al. Bile acids metabolism involved in the beneficial effects of Danggui Shaoyao San via gut microbiota in the treatment of CCl₄ induced hepatic fibrosis[J]. J Ethnopharmacol, 2024, 319( Pt 3): 117383. DOI: 10.1016/j.jep.2023.117383.
[36]	YANG SY, CHENG YJ, WANG XL, et al. Chinese herbal decoction, Yi-Qi-Jian-Pi formula exerts anti-hepatic fibrosis effects in mouse models of CCl₄-induced liver fibrosis[J]. Heliyon, 2024, 10( 5): e26129. DOI: 10.1016/j.heliyon.2024.e26129.